Canada Imaging Biomarkers Market

Canada Imaging Biomarkers Market Size Insights Forecasts to 2035

• The Canada Imaging Biomarkers Market Size was estimated at USD 615.33 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 11.57% from 2025 to 2035
• The Canada Imaging Biomarkers Market Size is Expected to Reach USD 2051.42 Million by 2035

According to a Research Report Published by Decisions Advisors and Consulting, The Canada Imaging Biomarkers Market Size is anticipated to Reach USD 2051.42 Million by 2035, rowing at a CAGR of 11.57% from 2025 to 2035. AI and machine learning are being incorporated into imaging analysis to speed up data processing, increase diagnostic precision and take market expansion to a new level. The market is expanding due to increased funding for translational and academic research institutions, as well as increased investment by biopharmaceutical companies in cancer research and drug development.

Market Overview

The market for Canadian imaging biomarkers is the area of the country's healthcare and diagnostics sector devoted to identifying biological markers that support disease detection, prognosis, and treatment monitoring through the use of medical imaging technologies. The market for imaging biomarkers is highly innovative due to developments in data analytics, artificial intelligence (AI), and imaging technologies. These developments make it possible to create more accurate and non-invasive diagnostic instruments, which promote early illness identification and individualised treatment regimens. In the imaging biomarkers sector, mergers and acquisitions are essential for fostering product development, market penetration, and innovation. Manufacturers, research labs, and academic institutions can collaborate to develop new imaging biomarker technologies and enhance existing ones. Moreover, Dr Craig Moore at Memorial University and other provincial researchers received more than CAD 1.2 million from the Canadian Institutes of Health Research (CIHR) recently for their creative biomarker projects that target diseases like cancer and multiple sclerosis. Through early detection and tailored treatments, this funding helps discover and validate biomarkers to enhance patient outcomes.

Report Coverage

This research report categorises the market for the Canada imaging biomarkers market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Canada imaging biomarkers market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Canada imaging biomarkers market.

Driving Factors

The imaging biomarkers market in Canada is growing and diversifying significantly due to a number of important factors. One of the main motivators is the growing need for personalised healthcare and precision medicine, where imaging biomarkers are essential for early disease detection, focused treatment, and better patient outcomes. The market demand is further driven by the increasing prevalence of chronic diseases like cancer, neurological disorders, and cardiovascular conditions, all of which call for precise diagnostic and monitoring tools. High-resolution multiplex biomarker imaging, immunohistochemistry, and fluorescent assays are among the technological developments in imaging modalities that are improving the capacity to view multiple biomarkers at once, enabling more thorough and precise disease characterisation.

Restraining Factors

The primary obstacles facing the Canadian imaging biomarkers market are the intricacy of disease heterogeneity, which makes it difficult to standardise biomarkers, the high expense and restricted availability of sophisticated imaging technologies, and regulatory barriers. Together, these elements present formidable obstacles to the wider uptake and expansion of imaging biomarkers in Canadian research and healthcare. ?

Market Segmentation

The Canada imaging biomarkers market share is classified into biomarker and technology.

• The quantitative imaging biomarkers segment held a significant share in 2024 and is projected to grow at a rapid pace over the forecast period.

The Canada imaging biomarkers market is segmented by biomarkers into anatomical biomarkers, functional biomarkers, molecular/nuclear biomarkers, quantitative imaging biomarkers, and others. Among these, the quantitative imaging biomarkers segment held a significant share in 2024 and is projected to grow at a rapid pace over the forecast period. The growing demand in clinical settings for accurate and repeatable measurements. QIBs facilitate personalized medicine approaches by offering objective data that can be used to evaluate the course of a disease and its response to treatment. Businesses are spending money creating and certifying QIBs in order to facilitate clinical adoption and regulatory approvals.

• The PET segment held a significant share in 2024 and is anticipated to grow at a rapid pace during the forecast period.

The Canada imaging biomarkers market is divided by imaging technology into MRI, CT, PET, SPECT, ultrasound, and others. Among these, the PET segment held a significant share in 2024 and is anticipated to grow at a rapid pace during the forecast period. The main causes of this are the growing applications in neurology and oncology, as well as the improvements in imaging technology. By making metabolic processes visible, PET imaging helps identify and track illnesses. By decreasing PET screen failure rates and improving the identification of qualified candidates for clinical trials, this approach improves trial efficiency by using initial blood-based biomarkers (BBMs) followed by amyloid PET scans for ambiguous cases. The clinical utility of PET scanners has increased due to technological advancements that have improved their sensitivity and resolution.

Competitive Analysis:

The report offers the appropriate analysis of the key organisations/companies involved within the Canada imaging biomarkers market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Imagia Cybernetics
• Synaptive Medical
• Therapixel Canada
• Circle Cardiovascular Imaging
• MIMOSA Diagnostics
• Clarius Mobile Health
• Prenuvo
• Others

Recent Developments:

• In June 2025, Columbia University's Centre for Innovation in Imaging Biomarkers and Integrated Diagnostics (CIMBID) made its formal debut with a daylong program of talks and activities that highlighted the centre's extensive experience using biomedical imaging data and artificial intelligence (AI) for personalised medicine. Multidisciplinary facility aimed at promoting clinical translation, education, and research in AI-driven imaging biomarkers and integrated diagnostics.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Canada, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the Canada Imaging Biomarkers Market based on the below-mentioned segments:

Canada Imaging Biomarkers Market, By

• Anatomical biomarkers
• Functional biomarkers
• Molecular/Nuclear Biomarkers
• Quantitative Imaging Biomarkers
• Others

Canada Imaging Biomarkers Market, By Process

• MRI
• CT
• PET
• SPECT
• Ultrasound
• Others